
    
      Single-centre, open-label, randomized, two-sequence, two-way crossover study. The study
      consisted of two consecutive single-dose treatment periods separated by a washout period of
      10 to 14 days or more. In Group 1 the volunteers received a single oral dose of 25 mg OPC. In
      Group 2 the volunteers received a single oral dose of 50 mg OPC
    
  